Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03647358 · ClinicalTrials.gov registry record · Phase 1

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

A Phase 1 study of Thyroid Carcinoma and Metastatic Thyroid Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT03647358 is a Phase 1 study of Thyroid Carcinoma and Metastatic Thyroid Carcinoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03647358, a Phase 1 study of Thyroid Carcinoma and Metastatic Thyroid Carcinoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new test determines sufficient radioiodine uptake in the cancer, treatment will continue as usual. However, if the new test shows only low radioiodine uptake, a decision may be made that the benefit from radioiodine therapy is insufficient and that another form of therapy is preferred.

Interventions

  • DEVICE PET/CT Scan
  • DRUG Iodine-124

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2018-08-21
Est. Completion 2027-08
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT03647358

The ClinicalTrials.gov registry entry for NCT03647358 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Thyroid Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which PET/CT Scan is the first listed.

NCT03647358 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03647358 about?

NCT03647358 is a clinical study titled "Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma". The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new test determines suffici...

What is the current status of trial NCT03647358?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2018-08-21. Estimated completion is 2027-08.

What conditions does trial NCT03647358 study?

This clinical trial studies the following conditions: Thyroid Carcinoma, Metastatic Thyroid Carcinoma.

What interventions are being tested in trial NCT03647358?

The interventions under investigation include: PET/CT Scan (DEVICE), Iodine-124 (DRUG).

Who is sponsoring clinical trial NCT03647358?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03647358 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Thyroid Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.